Working… Menu

BN83495 Phase I in Post-menopausal Women

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01840488
Recruitment Status : Completed
First Posted : April 25, 2013
Last Update Posted : April 25, 2013
Information provided by (Responsible Party):

Brief Summary:

The purpose of this study is to determine the optimal biological dose (OBD) of Irosustat (BN83495) in postmenopausal women with oestrogen receptor (ER) positive locally advanced or metastatic breast cancer with disease progression after prior hormonal therapy.

This study is designed to provide necessary information on safety and dose response of BN83495, when given by repeated once daily oral administration, while achieving a maximal STS inhibition and a maximal reduction in plasma oestradiol (E2) and adiol levels. The data obtained will be used to plan further clinical studies.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: Irosustat (BN83495) Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Dose Escalation Study To Determine The Optimal Biological Dose Of BN83495 - An Oral Steroid Sulphatase Inhibitor - In Postmenopausal Women With Oestrogen-Receptor Positive Breast Cancer Whose Disease Progressed After Prior Therapy For Locally Advanced/Metastatic Disease
Study Start Date : April 2007
Actual Primary Completion Date : September 2010
Actual Study Completion Date : September 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Irosustat (BN83495)
Single oral administration of irosustat
Drug: Irosustat (BN83495)

Three parts (A, B & C) open label, multiple cohort, dose escalation study with once daily administration of irosustat at 1, 5, 20, 40 and 80 mg. Patients treated in any cohort were not allowed to escalate to higher doses or be enrolled in another dosing cohort.

Part A - Single oral daily dose for 7 days, Part B - Repeated oral daily dose for 28 days and Part C - Repeated oral daily administration until disease progression.

Primary Outcome Measures :
  1. Change in percentage of steroid sulphatase (STS) inhibition in circulating Peripheral Blood Mononuclear Cells (PBMCs) after repeated daily therapy [ Time Frame: Days 15 and 36 ]
    The combined evaluation of ≥95% STS inhibition in PBMCs relative to Baseline after 7 and 28 days (Day 15 and Day 36,respectively) of continuous treatment and reduction in plasma E2 and adiol levels after 28 days of repeated daily administration, to determine the optimal biological dose (OBD) of irosustat.

Secondary Outcome Measures :
  1. Percentage of steroid sulphatase (STS) inhibition in circulating Peripheral Blood Mononuclear Cells (PBMCs) after a single dose [ Time Frame: Day 8 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Women over the age of 18 whose disease progressed after the first line of hormonal therapy for advanced or metastatic breast cancer.
  • Patients with no more than two prior hormonotherapy settings defined as adjuvant and first line of hormonotherapy Or - two lines of hormonotherapy given for advanced or metastatic disease
  • Patients with prior adjuvant hormonal therapy who relapse after 12 months of adjuvant treatment.
  • Patients with no more than two prior chemotherapy treatments defined as adjuvant and first line of chemotherapy Or two lines of chemotherapy given for advanced or metastatic disease Patients with no more than one prior therapy for Her2 positive breast cancer
  • Postmenopausal women, defined as: i) no spontaneous menses for a total of 2 years, ii) amenorrheic for at least 12 months with serum oestrogen level <30 pg/mL, and both LH/FSH >20 IU/L, chemotherapy-induced amenorrhea for at least 12 months, iii) bilateral oophorectomy, or radiation castration and amenorrheic for at least 3 months.
  • Histologically or cytologically confirmed breast cancer.
  • Laboratory documentation of ER-positive and/or progesterone receptor(PR) positive status.
  • ECOG performance status ≤2.
  • Adequate bone marrow function as determined by:

Haemoglobin >10 g/dL,Neutrophil count of >1.5 x 109 per litre, Platelet count of >75 x 109 per litre

  • Satisfactory hepatic function as measured by: serum bilirubin <1.5 ULN and either ALT or AST <2.5 x ULN (<5 x ULN in the presence of liver metastases). Alkaline phosphatase <2.5 ULN in the absence of liver metastases or <5 x ULN in the presence of liver or bone metastases.
  • Satisfactory renal function as measured by either a serum creatinine value of <1.5 x ULN or a creatinine clearance ≥60 mL/min.
  • Life expectancy of at least 12 weeks.
  • Patients with measurable or non-measurable lesions (RECIST criteria)
  • Patients included after the Optimal Biological Dose (OBD) is defined must have measurable lesion (RECIST criteria).

Exclusion Criteria:

  • Patients with progressive central nervous system metastases.
  • Patients with inflammatory breast cancer.
  • Patients with a marked baseline prolongation of QTc interval (e.g., repeated demonstration of a QTcf interval >450 ms).
  • Patients with a history of additional risk factors for TdP (e.g., heart failure, hypokalemia, family history of Long QT Syndrome).
  • Patients taking concomitant medications that are known to prolong the QTc interval (e.g., antihistamines, quinolones, antipsychotics etc).
  • Patients with pre-existing cardiac failure (American Heart Association Grade 3 or 4) or a myocardial infarction within the six months prior to the start of the study.
  • Patients with systolic and diastolic blood pressure below 100 and 60 mmHg respectively.
  • Patients with uncontrolled abnormalities of serum potassium, sodium, calcium or magnesium levels.
  • Patients with a coexisting significant disease or systemic infection.
  • Patients with uncontrolled diabetes (applicable only for the additional six patients included after the OBD is defined).
  • Patients who have malabsorption.
  • Patients who started biphosphonates therapy within 4 weeks prior to start of this study
  • Patients who are taking drugs that inhibit the carbonic anhydrase II (CAII) (e.g. acetazolamide, brinzolamide, dichlorphenamide, dorzolamide, methazolamide).
  • Patients who are taking coumarin like drugs (vitamin K antagonists).
  • Patients who are incapable of giving informed consent or complying with the protocol.
  • Patients who have received previous investigational therapies must have stopped those therapies for at least 4 weeks before treatment with BN83495.
  • Patients who have received previous therapy for this cancer within less than 1 month of entry in the study and/or who have received trastuzumab within less than 4 months of entry in the study, and/or fulvestrant within less than 2 months of entry.
  • Patients who have a history of hypersensitivity to the IMP or drugs with a similar chemical structure.
  • Patients who have a history of, or known current, problems with alcohol abuse.
  • Patients who have any mental condition rendering the patients unable to understand the nature, scope and possible consequences of the study, and/or evidence of an uncooperative attitude.
  • Patients who have abnormal baseline findings, any other medical condition or laboratory findings that, in the opinion of the Investigator, might jeopardise the patients' safety or decrease the chance of obtaining satisfactory data needed to achieve the objectives of the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01840488

Layout table for location information
Institut Jules Bordet
Bruxelles, Belgium, B- 1000
Centre Paul Papin
Angers, France, 49000
Institut Georges François Leclerc
Dijon, France, 21079
Centre Eugène Marquis
Rennes, France, 35042
United Kingdom
Imperial College Healthcare NHS Trust
London, United Kingdom, W12 0NN
Sponsors and Collaborators
Layout table for investigator information
Study Director: Medical Director Oncology Ipsen

Layout table for additonal information
Responsible Party: Ipsen Identifier: NCT01840488     History of Changes
Other Study ID Numbers: X-55-58064-002
First Posted: April 25, 2013    Key Record Dates
Last Update Posted: April 25, 2013
Last Verified: April 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases